^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iberdomide (CC-220)

    i
    Other names: CC-220, CC 220, CC220
    Company:
    BMS
    Drug class:
    CRL4-CRBN E3 ubiquitin ligase modulator
    Related drugs:
    4d
    EXCALIBER: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=939, Active, not recruiting, Celgene | Trial primary completion date: Mar 2026 --> Nov 2027
    Trial primary completion date
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    13d
    Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=88, Recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Recruiting
    Enrollment open
    |
    dexamethasone • Blenrep (belantamab mafodotin-blmf) • iberdomide (CC-220)
    16d
    ICON: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (clinicaltrials.gov)
    P2, N=60, Recruiting, Amsterdam UMC, location VUmc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • carfilzomib • iberdomide (CC-220)
    18d
    CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=466, Active, not recruiting, Celgene | Trial completion date: Feb 2028 --> Jul 2028
    Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • dexamethasone • iberdomide (CC-220)
    26d
    IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. (PubMed, J Gastroenterol Hepatol)
    IKZF3 drives GC progression and oxaliplatin resistance by activating PI3K/AKT/mTOR signaling. It is a potential prognostic biomarker and therapeutic target, supporting further development of LY294002 and Iberdomide for GC treatment.
    Journal
    |
    IKZF3 (IKAROS Family Zinc Finger 3)
    |
    oxaliplatin • LY294002 • iberdomide (CC-220)
    1m
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    1m
    Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI)
    New P1/2 trial
    |
    cyclophosphamide • topotecan • Qarziba (dinutuximab beta) • iberdomide (CC-220) • Unituxin (dinutuximab) • Leukine (sargramostim)
    1m
    Expanded Access for Iberdomide (clinicaltrials.gov)
    P=N/A, N=0, Available, Bristol-Myers Squibb
    New trial
    |
    iberdomide (CC-220)
    2ms
    CC-220-DLBCL-001: A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects with untreated aggressive B-cell lymphoma (2023-506094-35-00)
    P1, N=112, Active, not recruiting, Celgene Corp.
    New P1 trial
    |
    iberdomide (CC-220)
    2ms
    Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM. (PubMed, Eur J Haematol)
    With frontline therapeutic strategies increasingly employing quadruplet induction regimens and prolonged lenalidomide maintenance, resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators (CELMoDs) capable of overcoming IMiD refractoriness and enhancing the immunologic microenvironment. Iberdomide (CC-220) and mezigdomide (CC-92480) are rationally engineered CELMoDs designed to achieve deeper degradation of Ikaros (IKZF1) and Aiolos (IKZF3), restore cereblon-mediated activity, and potentiate immune effector responses...We examine how their pharmacodynamic properties differ from classical IMiDs, their relevance in triple-class and penta-refractory MM, and their integration into emerging combination strategies with monoclonal antibodies and T-cell-redirecting immunotherapies. Special emphasis is placed on ongoing and future trials that may refine their therapeutic positioning, alongside a critical appraisal of the limitations and future directions of this rapidly advancing drug class.
    Review • Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    lenalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    2ms
    Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM (ChiCTR2600117745)
    P3, N=1216, Recruiting, Peking University People's Hospital; Peking University People's Hospital
    New P3 trial
    |
    lenalidomide • iberdomide (CC-220)
    3ms
    A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • Empliciti (elotuzumab) • iberdomide (CC-220)